Abstract:Cancer treatment causes hearing loss, associated with the administration of chemotherapy and radiotherapy. Cyclophosphamide increased the risk of causing hearing loss. Complaints of tinnitus and speech understanding difficulty were observed.
“…Concerning the radiotherapy treatment, our findings showed a significant association with the occurrence of tinnitus, corroborating with Oliveira et al (2016), who also found toxic effects on the hearing of women who received the same treatment for ovarian, cervical, and uterine cancer 23 . Breast cancer treatment showed tinnitus (49.2%) as the main symptom of sequelae of the auditory system, with few occurrences of hearing loss (7.7%).…”
Section: Discussionsupporting
confidence: 92%
“…Regarding radiotherapy, although most studies indicate a strong relationship of ototoxicity to head and neck tumors [32][33][34] , simultaneous administration to chemotherapeutic agents can potentiate the effects of cell apoptosis in the cochlea 35 . Previous investigations that have verified the effect of treatment with chemotherapy and radiotherapy on breast, cervical and uterine neoplasms in the auditory system report the presence of hearing loss in both treatments 23 . Therefore, this study analyzed the occurrence of tinnitus and peripheral sensory neuropathy in women during chemotherapy for breast cancer.…”
mentioning
confidence: 83%
“…The literature reports a high degree of ototoxicity to platinum chemotherapy group 4,17,19 , followed by vincristine sulfate, doxorubicin hydrochloride, and epirubicin 19 . Cyclophosphamide's potential to affect the auditory system has been reported, both in the isolated form at low dosages 18 and along with other drugs 23 .…”
Objective: To analyze the occurrence of tinnitus and peripheral sensory neuropathy in women during breast cancer chemotherapy. Methods: This is a retrospective analytical study with a quantitative approach, performed in medical records of an oncology outpatient service between February 2014 and February 2015, using the toxicities scores of Common Terminology Criteria for Adverse Events (CTCAE). Results: Considering 181 patients with breast cancer who met the inclusion criteria, 49.2% reported tinnitus at some point of the treatment, while 65.1% peripheral sensory neuropathy. In both conditions, the predominant severity score was grade 1, with frequencies of 23.8% and 33.1%, respectively. A significant, positive and weak correlation was observed between the severity of tinnitus and peripheral sensory neuropathy (ρ = 0.325 and p = 0.001), as well as very weak between the number of complete cycles of chemotherapy and tinnitus (ρ = 0.195 and p = 0.009) and neuropathy peripheral sensory (ρ = 0.237 and p = 0.002). Conclusions: Tinnitus and peripheral sensory neuropathy were frequent toxicities during chemotherapy treatment of breast cancer, and both manifested with low severity/functional impact in most participants.
“…Concerning the radiotherapy treatment, our findings showed a significant association with the occurrence of tinnitus, corroborating with Oliveira et al (2016), who also found toxic effects on the hearing of women who received the same treatment for ovarian, cervical, and uterine cancer 23 . Breast cancer treatment showed tinnitus (49.2%) as the main symptom of sequelae of the auditory system, with few occurrences of hearing loss (7.7%).…”
Section: Discussionsupporting
confidence: 92%
“…Regarding radiotherapy, although most studies indicate a strong relationship of ototoxicity to head and neck tumors [32][33][34] , simultaneous administration to chemotherapeutic agents can potentiate the effects of cell apoptosis in the cochlea 35 . Previous investigations that have verified the effect of treatment with chemotherapy and radiotherapy on breast, cervical and uterine neoplasms in the auditory system report the presence of hearing loss in both treatments 23 . Therefore, this study analyzed the occurrence of tinnitus and peripheral sensory neuropathy in women during chemotherapy for breast cancer.…”
mentioning
confidence: 83%
“…The literature reports a high degree of ototoxicity to platinum chemotherapy group 4,17,19 , followed by vincristine sulfate, doxorubicin hydrochloride, and epirubicin 19 . Cyclophosphamide's potential to affect the auditory system has been reported, both in the isolated form at low dosages 18 and along with other drugs 23 .…”
Objective: To analyze the occurrence of tinnitus and peripheral sensory neuropathy in women during breast cancer chemotherapy. Methods: This is a retrospective analytical study with a quantitative approach, performed in medical records of an oncology outpatient service between February 2014 and February 2015, using the toxicities scores of Common Terminology Criteria for Adverse Events (CTCAE). Results: Considering 181 patients with breast cancer who met the inclusion criteria, 49.2% reported tinnitus at some point of the treatment, while 65.1% peripheral sensory neuropathy. In both conditions, the predominant severity score was grade 1, with frequencies of 23.8% and 33.1%, respectively. A significant, positive and weak correlation was observed between the severity of tinnitus and peripheral sensory neuropathy (ρ = 0.325 and p = 0.001), as well as very weak between the number of complete cycles of chemotherapy and tinnitus (ρ = 0.195 and p = 0.009) and neuropathy peripheral sensory (ρ = 0.237 and p = 0.002). Conclusions: Tinnitus and peripheral sensory neuropathy were frequent toxicities during chemotherapy treatment of breast cancer, and both manifested with low severity/functional impact in most participants.
“…O aumento da ocorrência de câncer é decorrente do envelhecimento da população e da elevada prevalência dos fatores de risco, ou seja, devido ao estilo de vida contemporâneo que pode favorecer a formação de tumores (Torre et al, 2012). O tratamento do câncer pode ser realizado por meio de cirurgia, quimioterapia, hormonioterapia e, em alguns casos, transplante de medula óssea Santos et al (2011) ou ainda pela utilização de diferentes classes de medicamentos, como aminoglicosídeos, agentes antineoplásicos, antibióticos, anti-inflamatórios não esteroidais, diuréticos, entre outros (Oliveira et al, 2016).…”
Objetivo: Descrever o perfil de pacientes oncológicos, no início do tratamento, em uso de medicamentos contínuos, assistidos em um CACON. Método: Trata-se de um estudo transversal, quantitativo e analítico. A amostra constituiu-se por pacientes com diagnóstico de câncer inseridos para iniciar o tratamento oncológico junto ao Centro de Alta Complexidade (CACON), avaliados no período de agosto de 2018 a janeiro de 2019. Resultados: Participaram da pesquisa 270 pacientes, 53% do sexo feminino e 58,1% com mais de 60 anos de idade. Verificou-se associação entre uso de medicamentos e: sexo feminino (p=0,025); ser casado ou ter acompanhante (p=0,049); e possuir mais de 60 anos (p=0,000). O grupo de medicamentos mais utilizado pelos pacientes oncológicos em tratamento com medicamentos contínuos foi do aparelho cardiovascular (69,56%). Verificada associação entre usar medicamentos contínuos e autorrelato de: hipertensão (p=0,000); diabetes mellitus (p=0,013); infarto agudo do miocárdio (p=0,045); depressão (p=0,001) e uso de bebidas alcóolicas (p=0,000). Conclusão: O estudo permitiu conhecer o perfil de uso de medicamentos contínuos e as variáveis associadas, estes dados são fundamentais para propor medidas que melhorem a efetividade e segurança da quimioterapia e dos demais medicamentos associados.
“…Different classes of medications are used in the treatment of cancer, such as aminoglycosides, anti-tumor agents, antibiotics, non-steroidal anti-inflammatory drugs, diuretics and anti-hypertensive agents, some of which are considered ototoxic (3) . Medications derived from platinum are the most devastating and have the following side effects when used at cumulative doses higher than 360 mg/m 2 : nausea, vomiting, nephrotoxicity, myeolsuppression and ototoxicity (4) .…”
RESUMO Objetivo Fazer um levantamento dos medicamentos ototóxicos utilizados no tratamento do câncer pediátrico, apontar os danos das drogas para o sistema auditivo e os métodos utilizados na identificação destes danos nessa população. Estratégia de pesquisa: Foram utilizados periódicos nacionais e internacionais pertinentes ao assunto, acessados eletronicamente em bases de dados da Biblioteca Virtual em Saúde - MS, PubMed, Biblioteca Digital Brasileira de Teses e Dissertações, que envolvessem a população pediátrica com histórico de tratamento oncológico, publicados entre 2007 e 2016, e no Banco de Teses e Dissertações da Coordenação de Aperfeiçoamento de Pessoal de Nível Superior. Critérios de seleção Foram selecionados estudos que contemplassem os seguintes critérios: estudos observacionais nas línguas portuguesa, inglesa ou espanhola e resumos disponíveis que informassem o método de avaliação do dano auditivo. Resultados A amostra final resultou em 12 artigos. Destes, a audiometria tonal limiar foi o método de avaliação auditiva mais utilizado, estando presente em 10 (84,61%) dos estudos, seguido das emissões otoacústicas (46,15%). Todos os estudos foram desenvolvidos com pacientes que fizeram uso de cisplatina ou derivados da platina e, quanto ao dano auditivo, apenas 1 dos estudos incluídos não relatou presença de alteração na população estudada. Conclusão Os derivados da platina expressam papel importante no tratamento do câncer em diversos níveis e são os agentes ototóxicos mais citados em pesquisas. A cóclea é o local mais afetado, mais especificamente as células ciliadas externas. Os métodos de investigação da alteração auditiva mais utilizados são a audiometria tonal limiar e as emissões otoacústicas.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.